BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 28445152)

  • 21. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment.
    Sapisochin G; Facciuto M; Rubbia-Brandt L; Marti J; Mehta N; Yao FY; Vibert E; Cherqui D; Grant DR; Hernandez-Alejandro R; Dale CH; Cucchetti A; Pinna A; Hwang S; Lee SG; Agopian VG; Busuttil RW; Rizvi S; Heimbach JK; Montenovo M; Reyes J; Cesaretti M; Soubrane O; Reichman T; Seal J; Kim PT; Klintmalm G; Sposito C; Mazzaferro V; Dutkowski P; Clavien PA; Toso C; Majno P; Kneteman N; Saunders C; Bruix J;
    Hepatology; 2016 Oct; 64(4):1178-88. PubMed ID: 27481548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utility of DNA flow cytometry in distinguishing between malignant and benign intrahepatic biliary lesions.
    Wen KW; Rabinovitch PS; Wang D; Mattis AN; Ferrell LD; Choi WT
    Virchows Arch; 2020 Oct; 477(4):527-534. PubMed ID: 32296928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Keratin 19-expressing hepatocellular carcinoma and small-duct type intrahepatic cholangiocarcinoma show a similar postoperative clinical course but have distinct genetic features.
    Akita M; Ajiki T; Fukumoto T; Itoh T; Zen Y
    Histopathology; 2019 Sep; 75(3):385-393. PubMed ID: 31017316
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor ratio of unsaturated to saturated sulfatide species is associated with disease-free survival in intrahepatic cholangiocarcinoma.
    Huizing L; Chen L; Roeth AA; Heij LR; Flinders B; Bouwense SAW; Balluff B; Neumann UP; Heeren RMA; Olde Damink SWM; Vreeken RJ; Schaap FG
    Cell Oncol (Dordr); 2023 Jun; 46(3):629-642. PubMed ID: 36630049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum CYFRA 21-1 in Biliary Tract Cancers: A Reliable Biomarker for Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma.
    Huang L; Chen W; Liang P; Hu W; Zhang K; Shen S; Chen J; Zhang Z; Chen B; Han Y; Meng F; DeMorrow S; Yin X; Lai J; Liang L
    Dig Dis Sci; 2015 May; 60(5):1273-83. PubMed ID: 25487191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CA9 overexpression is an independent favorable prognostic marker in intrahepatic cholangiocarcinoma.
    Gu M
    Int J Clin Exp Pathol; 2015; 8(1):862-6. PubMed ID: 25755787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of stroma LOXL2 overexpression on the prognosis of intrahepatic cholangiocarcinoma.
    Bergeat D; Fautrel A; Turlin B; Merdrignac A; Rayar M; Boudjema K; Coulouarn C; Sulpice L
    J Surg Res; 2016 Jun; 203(2):441-50. PubMed ID: 27363654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of neutrophil distribution in cholangiocarcinoma.
    Mao ZY; Zhu GQ; Xiong M; Ren L; Bai L
    World J Gastroenterol; 2015 Apr; 21(16):4961-8. PubMed ID: 25945010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An immunostaining panel of C-reactive protein, N-cadherin, and S100 calcium binding protein P is useful for intrahepatic cholangiocarcinoma subtyping.
    Akita M; Sawada R; Komatsu M; Suleman N; Itoh T; Ajiki T; Heaton N; Fukumoto T; Zen Y
    Hum Pathol; 2021 Mar; 109():45-52. PubMed ID: 33321161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular and cytogenomic profiling of hepatic adenocarcinoma expressing inhibinA, a mimicker of neuroendocrine tumors: proposal to reclassify as "cholangioblastic variant of intrahepatic cholangiocarcinoma".
    Braxton DR; Saxe D; Damjanov N; Stashek K; Shroff S; Morrissette JD; Tondon R; Furth EE
    Hum Pathol; 2017 Apr; 62():232-241. PubMed ID: 28232156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-mobility group box 1 expression and lymph node metastasis in intrahepatic cholangiocarcinoma.
    Xu YF; Ge FJ; Han B; Yang XQ; Su H; Zhao AC; Zhao MH; Yang YB; Yang J
    World J Gastroenterol; 2015 Mar; 21(11):3256-65. PubMed ID: 25805932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials.
    Lamarca A; Ross P; Wasan HS; Hubner RA; McNamara MG; Lopes A; Manoharan P; Palmer D; Bridgewater J; Valle JW
    J Natl Cancer Inst; 2020 Feb; 112(2):200-210. PubMed ID: 31077311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cirrhosis in intrahepatic cholangiocarcinoma: prognostic importance and impact on survival.
    Thakral N; Gonzalez T; Nano O; Shin SH; Samuels S; Hussein A
    BMC Gastroenterol; 2023 May; 23(1):151. PubMed ID: 37179301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition.
    Yang LX; Gao Q; Shi JY; Wang ZC; Zhang Y; Gao PT; Wang XY; Shi YH; Ke AW; Shi GM; Cai JB; Liu WR; Duan M; Zhao YJ; Ji Y; Gao DM; Zhu K; Zhou J; Qiu SJ; Cao Y; Tang QQ; Fan J
    Hepatology; 2015 Dec; 62(6):1804-16. PubMed ID: 26340507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterogeneity of small duct- and large duct-type intrahepatic cholangiocarcinoma.
    Kinzler MN; Schulze F; Jeroch J; Schmitt C; Ebner S; Gretser S; Bein J; Finkelmeier F; Trojan J; Zeuzem S; Schnitzbauer AA; Demes MC; Reis H; Wild PJ; Walter D
    Histopathology; 2024 May; 84(6):1061-1067. PubMed ID: 38409827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers.
    Liao H; Chen X; Wang H; Lin Y; Chen L; Yuan K; Liao M; Jiang H; Peng J; Wu Z; Huang J; Li J; Zeng Y
    Cancer Res; 2024 Jun; 84(11):1747-1763. PubMed ID: 38471085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MRPL27 contributes to unfavorable overall survival and disease-free survival from cholangiocarcinoma patients.
    Zhuang L; Meng Z; Yang Z
    Int J Med Sci; 2021; 18(4):936-943. PubMed ID: 33456351
    [No Abstract]   [Full Text] [Related]  

  • 38. Prognostic factors of intrahepatic cholangiocarcinoma after hepatic resection: univariate and multivariate analysis.
    Hanazaki K; Kajikawa S; Shimozawa N; Shimada K; Hiraguri M; Koide N; Adachi W; Amano J
    Hepatogastroenterology; 2002; 49(44):311-6. PubMed ID: 11995440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
    Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
    Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic impact of lymph node metastasis in distal cholangiocarcinoma.
    Kiriyama M; Ebata T; Aoba T; Kaneoka Y; Arai T; Shimizu Y; Nagino M;
    Br J Surg; 2015 Mar; 102(4):399-406. PubMed ID: 25611179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.